Modelling the epidemiological and economic impact of digital adherence technologies with differentiated care for tuberculosis treatment in Ethiopia
Authors:
- Lara GoscéLGLara Goscé
- Amare Worku TadesseATAmare Worku Tadesse
- Nicola FosterNFNicola Foster
- Kristian van KalmthoutKKKristian van Kalmthout
- Job van RestJRJob van Rest
- Jense van der WalJWJense van der Wal
- Martin J HarkerMHMartin J Harker
- Norma MaddenNMNorma Madden
- Tofik AbdurhmanTATofik Abdurhman
- Demekech GadissaDGDemekech Gadissa
- Ahmed BedruABAhmed Bedru
- Tanyaradzwa N DubeTDTanyaradzwa N Dube
Open Access
- 9 December 2024
- journal article
- research article
- Published by BMJ in BMJ Global Health
- Vol. 9 (12) , e016997
Abstract
Background: Digital adherence technologies (DATs) with associated differentiated care are potential tools to improve tuberculosis (TB) treatment outcomes and reduce associated costs for both patients and healthcare providers. However, the balance between epidemiological and economic benefits remains unclear. Here, we used data from the ASCENT trial to estimate the potential long-term epidemiological and economic impact of DAT interventions in Ethiopia. Methods: We developed a compartmental transmission model for TB, calibrated to Ethiopia and parameterised with patient and provider costs. We compared the epidemiological and economic impact of two DAT interventions, a digital pillbox and medication labels, to the current standard of care, assuming each was introduced at scale in 2023. We projected long-term TB incidence, mortality and costs to 2035 and conducted a threshold analysis to identify the maximum possible epidemiological impact of a DAT intervention by assuming 100% treatment completion for patients on DAT. Findings: We estimated small and uncertain epidemiological benefits of the pillbox intervention compared with the standard of care in Ethiopia, with a difference of −0.4% (95% uncertainty interval (UI) −1.1%; +2.0%) incident TB episodes and −0.7% (95% UI −2.2%; +3.6%) TB deaths. However, our analysis also found large total provider and patient cost savings (US$163 (95% UI US$118; US$211) and US$3 (95%UI: US$1; US$5), respectively, over 2023–2035), translating to a 50.2% (95% UI 35.9%; 65.2%) reduction in total cost of treatment. Results were similar for the medication label intervention. The maximum possible epidemiological impact a theoretical DAT intervention could achieve over the same timescale would be a 3% (95% UI 1.4%; 5.5%) reduction in incident TB and an 8.2% (95% UI 4.4%; 12.8%) reduction in TB deaths. Interpretation: DAT interventions, while showing limited epidemiological impact, could substantially reduce TB treatment costs for both patients and the healthcare provider.Keywords
Funding Information
- Unitaid Adherence Support Coalition to End TB (20193–3-ASCENT)
This publication has 44 references indexed in Scilit:
- The Impact of Digital Adherence Technologies on Health Outcomes in Tuberculosis: A Systematic Review and Meta-AnalysismedRxiv, 2024
- Digital adherence technologies to improve tuberculosis treatment outcomes in China: a cluster-randomised superiority trialThe Lancet Global Health, 2023
- Costs of digital adherence technologies for tuberculosis treatment supportmedRxiv, 2023
- Demonstrating multi-country calibration of a tuberculosis model using new history matching and emulation package - hmerEpidemics, 2023
- Effect of Digital Medication Event Reminder and Monitor-Observed Therapy vs Standard Directly Observed Therapy on Health-Related Quality of Life and Catastrophic Costs in Patients With TuberculosisJAMA Network Open, 2022
- In-Person vs Electronic Directly Observed Therapy for Tuberculosis Treatment AdherenceJAMA Network Open, 2022
- Digital Health Support in Treatment for TuberculosisNew England Journal of Medicine, 2019
- A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosisNature Medicine, 2018
- Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine modelsThe Lancet Global Health, 2016
- Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature ReviewPharmacoEconomics, 2015